Mounjaro vs Zepbound: Same Drug, Different Names

If you have been researching weight loss medications, you may have encountered both Mounjaro and Zepbound — and wondered what the difference is. The short answer: there is no difference in the medication itself. Both contain the exact same active ingredient, tirzepatide, manufactured by Eli Lilly. The difference is entirely about FDA-approved indications, brand naming, and, critically, how insurance handles each. This guide explains why one drug has two names and what that means for patients navigating their treatment options.

The Basics: What Is Tirzepatide?

Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. Unlike semaglutide (which targets only GLP-1 receptors), tirzepatide activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. This dual mechanism is believed to contribute to its impressive efficacy for both blood sugar control and weight loss.

In clinical trials, tirzepatide demonstrated average weight loss of 20-26% of body weight at the highest dose — results that approach those of some bariatric surgeries. For type 2 diabetes, it produced HbA1c reductions of up to 2.4%, placing it among the most effective glucose-lowering agents available.

Why Two Brand Names?

This practice is not unique to tirzepatide. The pharmaceutical industry regularly markets the same active ingredient under different brand names for different indications. Semaglutide follows the same pattern:

• Ozempic = semaglutide approved for type 2 diabetes
• Wegovy = semaglutide approved for weight management
• Mounjaro = tirzepatide approved for type 2 diabetes
• Zepbound = tirzepatide approved for weight management

The reasons for this are both regulatory and commercial. The FDA approves drugs for specific indications based on the clinical trials submitted. Eli Lilly ran separate trial programs for diabetes (SURPASS trials) and weight management (SURMOUNT trials), leading to separate approvals. Different brand names also allow for distinct marketing, pricing strategies, and insurance negotiations for each indication.

Mounjaro vs Zepbound: The Comparison Table

As you can see, the medication is identical. Same doses, same injection device, same frequency, same manufacturer. The only differences are the name on the box, the approved indication, and how your insurance categorizes it.

Insurance: Where the Real Difference Lives

For most patients, the practical difference between Mounjaro and Zepbound comes down to insurance coverage. This is where the two-name strategy becomes highly relevant:

Mounjaro (Diabetes Indication)

• Covered by most commercial insurance plans that include diabetes formularies
• Requires a type 2 diabetes diagnosis for on-label coverage
• Often subject to prior authorization demonstrating failure of other diabetes medications
• Medicare Part D generally covers Mounjaro for diabetes
• May be prescribed off-label for weight loss, but insurance typically will not cover this use

Zepbound (Weight Management Indication)

• Coverage is growing but remains inconsistent across insurance plans
• Many commercial plans still exclude weight loss medications from coverage
• Medicare currently does not cover weight loss medications (though the TREAT Act may change this)
• Requires BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity
• Eli Lilly offers a savings program for eligible commercially insured patients

This creates an unusual situation: a patient with both type 2 diabetes and obesity might get the same medication covered under one brand name but not the other, depending on which diagnosis the prescription is written for. Healthcare providers sometimes navigate this by prescribing Mounjaro with a diabetes diagnosis when it better serves the patient's insurance situation.

The Savings Card Landscape

Both medications have manufacturer savings programs, but the details differ:

• Mounjaro Savings Card: Eligible commercially insured patients may pay as little as $25 per monthly prescription. The program has undergone changes since launch, so check current terms.
• Zepbound Savings Card: Similar program available for commercially insured patients. Eli Lilly has also introduced a direct-to-consumer vial option for Zepbound at reduced prices for patients paying cash.

For patients without adequate insurance coverage, compounded tirzepatide through providers like Trimi may offer a more affordable pathway to the same medication.

Clinical Trial Differences

While the medication is identical, the clinical trial programs differed, which is why each has its own FDA approval:

SURPASS Trials (Mounjaro/Diabetes)

The SURPASS program included multiple trials evaluating tirzepatide in patients with type 2 diabetes. Key findings included HbA1c reductions of 1.9-2.4% and weight loss of 12-16% at the 15 mg dose — remarkable for a diabetes trial. These results led to Mounjaro's approval for type 2 diabetes in May 2022.

SURMOUNT Trials (Zepbound/Weight Management)

The SURMOUNT program enrolled patients with obesity or overweight (with comorbidities) but without diabetes. The SURMOUNT-1 trial showed average weight loss of 20.9% at the 15 mg dose over 72 weeks. The SURMOUNT-5 trial was a head-to-head comparison showing tirzepatide produced significantly greater weight loss than semaglutide 2.4 mg (20.2% vs 13.7%).

Which Should Your Doctor Prescribe?

Since the medication is identical, the prescribing decision typically depends on:

• Your diagnoses: If you have type 2 diabetes, Mounjaro is the on-label choice. If you have obesity without diabetes, Zepbound is on-label.
• Insurance coverage: Your provider may choose the brand name most likely to be covered by your specific plan.
• Savings programs: Depending on eligibility, one brand's savings card may offer better out-of-pocket pricing.
• Prior authorization requirements: Some plans have simpler approval pathways for one brand versus the other.

If you have both diabetes and obesity, your provider has more flexibility to prescribe whichever brand name secures better coverage or pricing.

Can You Switch Between Mounjaro and Zepbound?

Because they contain the same medication at the same doses, switching between Mounjaro and Zepbound is seamless. There is no need to re-titrate or adjust dosing. You simply continue your current dose under the new brand name. However, switching may be necessary if your insurance coverage or savings program changes.

The Bigger Picture: Tirzepatide's Role in Treatment

Regardless of which name it carries, tirzepatide represents a significant advance in both diabetes and obesity treatment. Its dual GIP/GLP-1 mechanism produces weight loss and glycemic control that exceed single-agonist GLP-1 medications in head-to-head trials. For patients exploring their options, the medication behind both brand names is among the most effective available.

If you are interested in learning whether tirzepatide is right for you, Trimi's medical team can help evaluate your health profile and guide you toward the most appropriate and affordable treatment option.

Frequently Asked Questions